Lung cancer screening: New guidelines, new challenges

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

Smoking is still the number one preventable cause of death in the U.S.​ and lung cancer is far and away the number one cause of cancer death in the U.S. 

To access this subscriber-only content please log in or subscribe.

If your institution has a site license, log in with IP-login or register for a sponsored account.*
*Not all site licenses are enrolled in sponsored accounts.

Login Subscribe
David Balis, MD
Professor, general internal medicine, Department of Internal Medicine, UT Southwestern Medical Center; Director, Smoking Cessation Clinics, Parkland and UT Southwestern
Table of Contents

YOU MAY BE INTERESTED IN

Tagrisso (osimertinib) demonstrated a sustained, clinically meaningful overall survival benefit at eight years compared to placebo in the adjuvant treatment of patients with early-stage (1B, 2, and 3A) epidermal growth factor receptor-mutated non-small cell lung cancer after complete tumor resection with curative intent, according to the updated exploratory results from the ADAURA phase III trial. 
David Balis, MD
Professor, general internal medicine, Department of Internal Medicine, UT Southwestern Medical Center; Director, Smoking Cessation Clinics, Parkland and UT Southwestern

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login